Poster: AML-432 Overall Survival (OS) by IDH2 Mutant Allele (R140 or R172) in Patients With Late-Stage, Mutant-IDH2 Relapsed/Refractory Acute Myeloid Leukemia (AML) Treated With Enasidenib or Conventional Care Regimens (CCR) in the Randomized, Open-Label, Phase 3 IDHENTIFY Trial

Authors :: Courtney D. DiNardo
Stéphane de Botton
Alberto Risueño
Andre C. Schuh
Bob Löwenberg
Hee-Je Kim
Paresh Vyas
Andrew H. Wei
Eytan M. Stein
Hartmut Döhner
Amir T. Fathi
Patricia Martin-Regueira
Lilia Taningco
Iryna Bluemmert
Xin Yu
Wendy L. See
Maroof Hasan
Source :: Clinical Lymphoma Myeloma and Leukemia. 22:S124
Publication Year :: 2022
Publisher :: Elsevier BV, 2022.

Tools